Viemed Healthcare, Inc. (NASDAQ:VMD) Shares Sold by Ulland Investment Advisors LLC

Ulland Investment Advisors LLC lessened its stake in Viemed Healthcare, Inc. (NASDAQ:VMD) by 23.0% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 19,560 shares of the company’s stock after selling 5,850 shares during the period. Ulland Investment Advisors LLC owned about 0.05% of Viemed Healthcare worth $157,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. JPMorgan Chase & Co. boosted its position in shares of Viemed Healthcare by 151.7% during the third quarter. JPMorgan Chase & Co. now owns 98,798 shares of the company’s stock worth $724,000 after buying an additional 59,538 shares during the period. Barclays PLC boosted its holdings in Viemed Healthcare by 342.3% during the 3rd quarter. Barclays PLC now owns 53,439 shares of the company’s stock valued at $392,000 after acquiring an additional 41,358 shares during the period. National Bank of Canada FI boosted its holdings in Viemed Healthcare by 91.2% during the 3rd quarter. National Bank of Canada FI now owns 3,346 shares of the company’s stock valued at $25,000 after acquiring an additional 1,596 shares during the period. Wasatch Advisors LP grew its position in Viemed Healthcare by 19.6% in the 3rd quarter. Wasatch Advisors LP now owns 1,848,884 shares of the company’s stock valued at $13,552,000 after acquiring an additional 303,277 shares in the last quarter. Finally, Raffles Associates LP increased its stake in Viemed Healthcare by 11.0% during the third quarter. Raffles Associates LP now owns 402,691 shares of the company’s stock worth $2,952,000 after purchasing an additional 40,000 shares during the period. Hedge funds and other institutional investors own 74.24% of the company’s stock.

Viemed Healthcare Stock Down 0.2 %

Shares of VMD opened at $8.15 on Tuesday. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.19 and a current ratio of 1.31. The stock has a market capitalization of $317.36 million, a PE ratio of 30.19 and a beta of 1.47. The company’s 50-day simple moving average is $8.41 and its 200-day simple moving average is $7.96. Viemed Healthcare, Inc. has a 1 year low of $6.21 and a 1 year high of $10.44.

Viemed Healthcare (NASDAQ:VMD) last issued its quarterly earnings results on Wednesday, November 6th. The company reported $0.10 EPS for the quarter, beating the consensus estimate of $0.08 by $0.02. Viemed Healthcare had a net margin of 4.87% and a return on equity of 8.72%. The company had revenue of $58.00 million during the quarter.

Insider Buying and Selling

In related news, Director Nitin Kaushal sold 30,000 shares of the firm’s stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $9.56, for a total value of $286,800.00. Following the sale, the director now owns 126,843 shares of the company’s stock, valued at $1,212,619.08. This trade represents a 19.13 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Randy E. Dobbs sold 36,261 shares of the business’s stock in a transaction that occurred on Wednesday, November 13th. The stock was sold at an average price of $9.28, for a total transaction of $336,502.08. Following the transaction, the director now owns 107,706 shares of the company’s stock, valued at $999,511.68. This trade represents a 25.19 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 72,256 shares of company stock valued at $674,739 in the last three months. 20.00% of the stock is owned by corporate insiders.

Viemed Healthcare Profile

Viemed Healthcare, Inc, together with its subsidiaries, provides home medical equipment (HME) and post-acute respiratory healthcare services to patients in the United States. It provides respiratory disease management solutions, including treatment of chronic obstructive pulmonary disease (COPD), which include non-invasive ventilation, percussion vests, and other therapies; and invasive and non-invasive ventilation and related equipment and supplies to patients suffering from COPD.